Purpose of review
INTRODUCTION
Allergen immunotherapy (AIT) is currently the only disease-modifying treatment for allergic rhinitis, which is a condition affecting up to 25% of the worldwide population [1] . Apart from its capacity to decrease the symptoms and the need of reliever therapy, AIT is also able to provide long-term protection after therapy discontinuation. Moreover, AIT prevents the onset of asthma in patients with allergic rhinitis [2] . Numerous explorative studies and clinical trials have been performed to elucidate the underlying mechanisms of AIT 
BIOLOGICAL FUNCTIONS OF IL-35
IL-35 was discovered by two independent groups in 2007 in an almost simultaneous manner [7, 8] . IL-35 is a relatively novel anti-inflammatory cytokine, belonging to the IL-12 superfamily (composed of other members such as IL-12, IL-23, and IL-27). It consists of two chains, IL-12a chain p35 and IL-27a chain EpsteinBarr virus-induced gene 3 (Ebi3), linked by a disulphide bond [9] . IL-35 binds to IL-35 receptor, which is composed of IL-12Rb2 and gp130 subunits in T cells or IL-27Ra and IL-12Rb2 in B cells [9] . The binding of IL-35 to its receptor leads to the activation of signal transducers and activators of transcription (STAT) pathways: STAT1 and STAT4 pathways in T cells, or STAT 1 and STAT3 in B cells [10] .
IL-35 is unique to other members of the IL-12 superfamily in their expression and secretion pattern. Although other cytokine members of IL-12 superfamily are produced by activated antigen presenting cells (B cells, monocytes, macrophages, and dendritic cells), IL-35 is predominantly secreted by Treg cells [7] and regulatory B (Breg) cells [11, 12] . Breg cells are a subset of B cells that have the ability to produce regulatory cytokine IL-10, hence bearing anti-inflammatory properties. Several Breg phenotypes have been identified in human peripheral blood based on their surface markers. They are categorized into transitional B cells ( [11, 12] . These B cell-derived IL-35, which have an autocrine role to further expand Breg cells, can subsequently enhance the activity of T cell-induced FoxP3 þ Treg cells [9, 12, 14] . Further to this, studies from in vivo murine model also reported the ability of recombinant IL-35 protein to promote Breg cell proliferation purified from mouse spleen, characterized by surface markers CD19 þ CD5 þ B220 lo [15] . In addition to its biological role in immune cells, IL-35 has been shown to be essential for the maximal suppressive activity of Treg cells [9] [16] , whereas also having the ability to inhibit Th2 development through GATA3 and IL-4 repression. In addition to these effects, IL-35 mediates the conversion of Th2 cells into Treg cells, which is reversible in the presence of IFN-g [17] (Fig. 1) .
Although murine studies have shown the immunosuppressive ability of IL-35, its effects in human disease remain largely unstudied [18, 19] . Although a preliminary work reported decreased IL12A and EBI3 mRNA expression, together with low-serum IL-35 in allergic rhinitis patients [20] , very limited studies have further elaborated the role of this cytokine in respiratory allergy [21, 22] 
ALLERGEN IMMUNOTHERAPY
AIT is indicated in allergic rhinitis patients who do not respond to conventional pharmacotherapies such as antihistamines or nasal corticosteroids [23] . The prescription of AIT should be guided by the patient's symptom pattern and the proven IgEsensitizations to aeroallergens [24] . Because of its unique disease-modifying effect, AIT appears as a specially appealing therapeutic option for allergic individuals. Nevertheless, a significant proportion of allergic rhinitis patients do not respond satisfactorily to AIT, even when the indication criteria are properly met [25] . In the clinical practice, AIT is administered through the subcutaneous (SCIT) or the sublingual (SLIT) routes. SCIT requires a buildup phase involving 2-4 weekly up-dosing injections, followed by a maintenance phase of monthly subcutaneous doses for a minimum period of 3 years [25] . On the other hand, SLIT involves daily tablets or drops placed under the tongue. Although SCIT should be injected in a clinical setting because of the risk of systemic allergic reactions, SLIT can be administered safely at the patients' home [25, 26] . ]. When given continuously for a minimum of 3 years, both SCIT and SLIT have proven to be disease-modifying therapies, offering a long-term reduction of clinical symptoms for several years after AIT discontinuation [27] . This longterm benefit sets them apart from other therapeutic strategies such as antihistamines, corticosteroids, and monoclonal antibodies [27] .
MECHANISM OF SUBLINGUAL IMMUNOTHERAPY
Multiple studies and clinical trials have been performed in an effort to increase the understanding of the underlying mechanisms of AIT. SLIT-induced tolerance involves a complex and orchestrated immune response, which includes changes in the humoral response, inhibition of Th2 cells, immune deviation toward a type 1 response, and induction of regulatory T and B cells. In addition to this, successful grass pollen immunotherapy has also been associated with inhibition of eosinophils recruitment and activation, which correlated with clinical symptoms [28] (Fig. 2) .
Humoral responses following sublingual immunotherapy
The modification of humoral responses following SLIT treatment is evidenced by the transient early increase in allergen-specific IgE antibody levels [29] . In individuals suffering seasonal allergic rhinitis, this early phenomenon is followed by a blunting of the natural seasonal increases in IgE level upon allergen exposure [29] . It has been speculated that this initial increase in IgE level (reflecting an enhanced Th2 priming), induced by the natural exposure to high allergen concentrations is key in the success of immunotherapy. Nevertheless, these early increases ultimately result in a reduction of allergen-specific IgE antibodies when SLIT is administered for several years. This depletion of IgE potentially contributes to the long-term tolerogenic effect [30, 31] . To complement this, SLIT has been illustrated to induce allergen-specific IgG 1 [32] , IgG 4 , and IgA 1 and IgA 2 [27, 33] antibodies, all of which have been shown to have inhibitory capacity. Specific IgG 4 antibodies with inhibitory capacity for IgE-facilitated allergen presentation were also observed in the nasal fluid of SLIT patients [29] .
Modulation of dendritic cells by sublingual allergen immunotherapy
Dendritic cells act as antigen-presenting cells and are known to play a role in the initiation and maintenance of allergic inflammation. However, in addition to this, they are also known to support the induction of immune tolerance. It has been previously shown that SLIT treatment can result in a significant reduction of the maturation status and the number of peripheral dendritic cells while increasing the proportion of regulatory dendritic cells [34, 35] . Further analysis illustrated that changes in the balance of regulatory dendritic cell to dendritic cells can be observed from 4 months of SLIT treatment and that these changes are associated with a reduction in rhinoconjunctivitis symptoms [34] . In a separate study involving AIT in house dust mite (HDM)-allergic children, 1 year of SLIT resulted in an increase in IL-10 secretion and reduced ability for dendritic cells to mature [36] .
Deletion of Th2 cells and immune deviation toward a type 1 response
A successful SLIT has also been associated with a decrease in Th2 cell numbers and immune deviation toward Th1 response [4] . The Gauging Responses in Allergic Rhinitis to SCIT versus SLIT (GRASS) trial illustrated that a 2-year SLIT treatment resulted in a clinical improvement accompanied by a decrease in peripheral allergen-specific
& ]. This was also complemented by a reduction in the level of local Th2 cytokines (IL-4, IL-5, IL-13) in the nasal secretions following nasal allergen challenge [27, 38] . The reductions in local Th2 cytokines and circulating Th2 cell numbers were lost 1 year after discontinuation of the 2-year treatment cycle, resulting in the recurrence of clinical symptoms. These observations highlight the importance of Th2 suppression in mediating long-term tolerance [27, 38] . This reduction of Th2 immune responses has also been associated with immune deviation toward a type 1 immune response [38] . Though most studies have focused on SCIT, it has been illustrated that successful AIT results in increased allergen-triggered IFNG mRNA in T cells [38] , a downregulation in IL5/IFNG mRNA in mucosal resident cells, and elevated nasal IFN-g level [39] . A birch SCIT study also observed a reduction in the ratio of Bet v 1-specific IL-5/IFN-g-producing cells [40, 41] . Finally, deletion of Th2 cells has been shown to result in an increase in Th1 populations [42] .
INDUCTION OF REGULATORY B CELLS DURING IMMUNOTHERAPY
One of the prominent mechanisms underlying AIT-induced immune tolerance is the generation of Breg and Treg cells. Breg cells are armed with the capacity to produce IL-10. This immunomodulatory cytokine can suppress T cell and dendritic cellmediated inflammatory responses [43] . A study illustrated that purified IL-10-producing Breg cells from bee venom tolerant individuals were able to inhibit allergen-specific T cell proliferation [44] . More recently, TGF-b and IL-35 have also been involved in the suppressive capacity of Breg cells [43] . It has been reported that recombinant IL-35 can mediate the production of IL-10 and IL-35 by B cells. Importantly, IL-35 has been shown to enhance the activity of T cell-induced FoxP3 þ Treg cells [11, 12, 14] . A recent study provided insightful data regarding the capacity of Breg cells to modulate T follicular helper cell responses [45] . Although it is likely that the IL-35 derived from B cells plays a beneficial role in grass pollen AIT, more studies are required to fully elucidate the potential role of this cytokine. 
INDUCTION OF REGULATORY T CELLS DURING IMMUNOTHERAPY
SLIT has been associated with the induction of both natural Treg cells (expressing transcription factor FoxP3) and inducible Treg cells with the capacity to produce regulatory cytokines, such as IL-10, TGF-b, and IL-35 [33, 46, 47] . In a grass pollen SLIT treatment, immunofluorescence experiments of sublingual biopsy specimens illustrated an increase in FoxP3 þ cell numbers in the local mucosal [4] . Further to this, a randomized controlled study of dual grass pollen and house dust mite SLIT observed that 1 year after the initiation of the therapy, a reduction of CpG methylation could be detected within the FoxP3 locus of Treg cells from patients in the active group [48] . Inducible Treg (iTreg) cells can produce either IL-10 (Tr1), TGF-b (Th3), or IL-35 (iT R 35), and they have been shown to modulate allergen-driven T cell proliferation and the production of Th2 cytokines [47] . A grass pollen immunotherapy study examining nasal biopsies collected before and during the 2 years of treatment [6 && ], demonstrated that successful AIT was associated with predominant iTreg cell responses in the nasal mucosa during the grass pollen season, together with increased IL-10 þ T cells and allergen-specific IgG 4 in peripheral blood. Moreover, the proportion of TGF-b þ T cells in the nasal mucosa following AIT positively correlated with peripheral circulating IgA concentrations [49] . Evidence for the induction of IL-10 þ Treg cells have also been reported following SLIT treatment targeted for both grass and birch pollens [32,50 & ].
More recently, a cross-sectional study from our group has shown that IL-35 (measured in culture supernatants) and iT R 35 are dysregulated in untreated seasonal allergic rhinitis patients compared to healthy study participants. However, grass pollen SLIT treatment for a minimum period of 12 months was able to restore the homeostatic levels [6 && ]. It was further elaborated that IL-35 and iT R 35 were able to suppress IL-5 and IL-13 production by type 2 innate lymphoid cells, allergen-driven T cell proliferative responses, and Th2 cytokine production. Further to this, it was also shown that IL-35 is able to inhibit IgE production by B cells and to impair Th2 cell polarization and dendritic cell-mediated cytokine production. Though a validation in a bigger clinical trial is still required, these observations suggest the involvement of iT R 35 and IL-35 in SLIT-mediated immune tolerance and, pave the way for their potential use as response biomarkers.
CONCLUSION
The long-term clinical benefit achieved by SLIT requires the orchestration of a complex network of immune responses. Despite its well-established clinical effectiveness of AIT for respiratory allergy, additional efforts need to be invested to unravel new response biomarkers. IL-35 has emerged as a novel cytokine with immunomodulatory features, posing as a potential key player in the induction of tolerance following SLIT treatment. These findings also highlight novel treatment strategies aiming to enhance the immunomodulatory properties of IL-35. A greater understanding of SLIT mechanisms has also suggested the potential utility of IL-35 and iT R 35 as surrogate immunological biomarker to assess the clinical efficacy of AIT. Large clinical studies will permit the validation of these findings and the investigation of their applicability to predict and monitor the response to AIT in patients with allergic rhinitis. 
